The position of neoadjuvant chemotherapy in the treatment of non-small-cell lung carcinoma

Czech version

Authors: I. Špásová
Authors‘ workplace: Pneumologická klinika 2. lékařské fakulty UK a FN Motol, Praha, přednosta doc. MUDr. Jaromír Musil, Ph. D.
Published in: Vnitř Lék 2007; 53(6): 715-723
Category: Reviews

Overview

Surgical treatment of patients with non-small-cell lung carcinoma (NSCLC) offers greatest chances for long-term survival. However, the treatment is applicable only to patients diagnosed at an early stage of the disease, i.e. at stage I or II. The five year survival rate of patients operated at stage IIIA is as low as 23 %. Hence there is a great need for improving survival results, especially in the sphere of systemic chemotherapy, as most tumour relapses involve the formation of metastases. Even though neoadjuvant chemotherapy in the operable stages of NSCLC still appeared very promising as a method of treatment a couple of years ago, recently published results have shown that its role has not yet been fully clarified and is still a subject of research. Additional results from randomised studies are necessary before neoadjuvant therapy may become a treatment standard. The dilemma as to whether or not to apply adjuvant, neoadjuvant or both types of chemotherapy in patients operated on for NSCLC therefore remains unsolved. On the whole, the positive role of neoadjuvant chemotherapy does not appear to be proven in the treatment of operable stage I and II NSCLS. In contrast, results of randomised studies first published in 2004 were in favour of post-surgical adjuvant chemotherapy as opposed to surgical treatment alone in NSCLC stage IB, II and IIIA. The question of whether it is better to apply chemotherapy prior to or after surgery can only be answered by the extensive randomised studies underway. The role of neoadjuvant chemotherapy in patients with NSCLC at clinical stage IIIA remains uncertain. The most rational approach to such patients appears to be neoadjuvant chemotherapy or chemotherapy with subsequent surgery.

Key words:
non-small-cell lung carcinoma – NSCLC – neoadjuvant chemotherapy of NSCLC – induction chemotherapy of NSSCLC – adjuvant chemotherapy of NSCLC – surgical treatment of NSCLC

Sources

1. Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(Suppl 4): 225-233.

2. Bunn PA jr. Future directions in clinical research for lung cancer. Chest 1994; 106: 399S-407S.

3. Pantel K, Izbicki J, Passlick B et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without over metastases. Lancet 1996; 347: 649-653.

4. Bulzebruck H, Bopp R, Drings P et al. New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-1110.

5. Non-Smal Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: Meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.

6. Splinter TA. Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 1990; 26: 1093-1099.

7. Souquet PJ, Chauvin F, Boissel JP et al. Polychemotherapy in advanced non small cell lung cancer. Lancet 1993; 342: 19-21.

8. Bunn PA jr, Kelly K. New chemoterapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1097-1100.

9. Ohgami A, Mitsudomi T, Sugio K et al. Micrometastatic tumor cells in the bone marrow of patients with completely resected non-small-cell lung cancer. Ann Thorac Surg 1997; 64: 363-367.

10. D’Cunha J, Corfits AL, Herndon JE 2nd et al. Molecular staging of lung cancer: realtime polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer – preliminary results of Cancer and Leukemia Group B trial 9761. J Thorac Cardiovasc Surg 2002; 123: 484-491.

11. Kurusu Z, Yamashita J, Ogawa M et al. Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small cell lung cancer. Surgery 1999; 126: 820-826.

12. Pisters KMW, Ginsberg RJ, Giroux DJ et al. Induction chemotherapy before surgery for early-stage lung cancer: A novel aproach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119: 429-439.

13. Eberhardt WE, Albain KS, Pass H et al. Induction treatment before surgery for non-small cell lung cancer. Lung Cancer 2003; 42(Suppl 1): S9-S14.

14. Ginsberg RJ. Neoadjuvant (induction) treatment for non-small cell lung cancer. Lung Cancer 1995; 12(Suppl 1): S33-S40.

15. Rusch VW, Albain KS, Crowley JJ et al. Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Ann Thorac Surg 1994; 58: 290-295.

16. Depierre A, Milleron B, Moro-Sibilot D et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253.

17. Gralla RJ, Kris MG, Burke MT et al. The influence of the addition of mitomycin to vindesine plus cisplatin in a random-assignment trial in 120 patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1986; 5: A182.

18. Martini N, Kris MG, Gralla RJ et al. The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 1988; 45: 370-379.

19. Rosell R, Maestre A, Font A et al. A randomized trial of Mitomycin/Ifosfamide/Cisplatin chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung. Semin Oncol 1994; 21: 28-33.

20. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.

21. Rosell R, Gómez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7-14.

22. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998; 21: 1-6.

23. Elias AD, Skarin AT, Leong T et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997; 17: 147-161.

24. Ichinose Y, Tsuchia R, Kato H Randomized trial of chemotherapy followed by surgery versus surgery for stage IIIA N2 non-small cell lung cancer: The Japan clinical oncology group (lung cancer surgical study group) 9209. Lung Cancer 2000; 29: Suppl 2: 173.

25. Shepherd FA, Johnston MR, Payne D et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group study. Br J Cancer 1998; 78: 683-685.

26. Le Chevalier T, Arriagada R, Tarayre M et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. Letter. J Natl Cancer Inst 1992; 84: 58.

27. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1892.

28. Burkes RL, Ginsberg RJ, Shepherd FA et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small cell lung cancer: results of the Toronto phase II trial. J Clin Oncol 1992; 10: 580-586.

29. Chella A, Lucchi M, Ribechini A et al. Pre-operative chemotherapy for stage IIIa non-small cell lung cancer. Eur J Surg Oncol 1995; 21: 393-397.

30. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: Mature results of a phase II trial. J Clin Oncol 1998; 16: 622-634.

31. Finkelstein EI, Urschel JD, Takita H Neoadjuvant chemotherapy for resectable non-small cell lung cancer. J Exp Clin Cancer Res 1997; 16: 437-439.

32. Kolek V, Grygárková I, Hajdúch M et al. Kombinace paklitaxel a karboplatina v neoadjuvantní chemoterapii u hraničně operabilních stádií IIIA nemalobuněčného karcinomu plic. Následná cílená pooperační adjuvantní chemoterapie. Stud Pneumol Phtiseol 2002; 62: 19-23.

33. Kolek V, Grygárková I, Hajdúch M et al. Neoadjuvantní chemoterapie u hraničně operabilních stádií IIIA nemalobuněčného karcinomu plic kombinací vinorelbin a karboplatina. Klinická Onkologie 2001; 14: 55-58.

34. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1374.

35. Palackdharry CS, Durham SJ, Durzinskyd S et al. Premilinary results of neoadjuvant Paclitaxel and Carboplatin in the treatment of early stage non-small-cell lung cancer. Sem Oncol 1997; 24: S12-34-S12-36.

36. Pešek M, Brůha F, Mukenšnábl P Indukční předoperační chemoterapie plicní rakoviny. Prakt Lék 1998; 78: 253-255.

37. Rice TW, Adelstein DJ, Ciezki JP et al. Short-Course induction chemoradiotherapy with paclitaxel for stage III non-small cell lung cancer. Ann Thorac Surg 1998; 66: 1909-1914.

38. Van Zandwijk N, Smith EF, Kramer GW et al. Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). J Clin Oncol 2000; 18: 2658-2664.

39. Betticher DC, Hsu Schmitz SF, Totsch M et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21: 1752-1759.

40. O´Brien ME, Splinter T, Smit EF et al. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer. An EORTC phase II study. Eur J Cancer 2003; 39: 1416-1422.

41. Cappuzzo F, Selvaggi G, Gregorc V et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB non-small cell lung carcinoma: an Italian Lung Cancer Project Observational Study. Cancer 2003; 98: 128-134.

42. Voltolini L, Luzzi L, Ghiribelli C et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 2001; 20: 1106-1112.

43. Špásová I, Hytych V, Petera J Účinnost a toxicita cisplatiny a vinorelbinu v léčbě III. stádia nemalobuněčné plicní rakoviny. Lék Zpr LF UK Hradec Králové 2000; 45: 103-111.

44. Špásová I, Petera J, Hytych V The Role of Neoadjuvant Chemotherapy in Marginally Resectable or Unresectable Stage III Non-Small Cell Lung Cancer. Neoplasma 2002; 49: 188-195.

45. Yang Ch, Tsai CM, Wang LS et al. Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer. Br J Cancer 2002; 86: 190-195.

46. Solomon B, Mitchell JD, Bunn PA Jr Adjuvant chemotherapy for resected non-small-cell lung cancer. Oncology (Williston Park) 2005; 19: 1685-1697, discussion 1698-1700, 1705.

47. Strauss GM, Herndon J, Maddaus MA et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 (Abstract 7019). J Clin Oncol 2004; 22: Suppl 14S: 621.

48. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. Report of National Cancer Institute of Canada Clinical Trials Group and National Cancer Institute of the United States Intergroup JBR.10. N. Engl J Med 2005; 352: 2589-2597.

49. Pisters K, Vallierres E, Bunn P et al. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (P/C) chemotherapy in early stage non-small cell lung cancer (NSCLC: preliminary results. Proc Am Soc Clin Oncol 2005; 24: A1095.

50. Scagliotti GV, Ch.E.S.T. Investigators. Preliminary results of Ch.E.S.T.: a phase III study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer (NSCLC). J Clin Oncol 2005; 23: Suppl 16S: A7023.

51. Belani CP Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 2005; 32: Suppl 2: S9-S15.